Analysis of the effect of bezafibrate on the oxygen dissociation curve of human hemoglobinWOOTTON, R.FEBS letters. 1984, Vol 171, Num 2, pp 187-191, issn 0014-5793Article

Exposure to human pharmaceuticals Carbamazepine, Ibuprofen and Bezafibrate causes molecular effects in Dreissena polymorphaCONTARDO-JARA, Valeska; LORENZ, Claudia; PFLUGMACHER, Stephan et al.Aquatic toxicology. 2011, Vol 105, Num 3-4, pp 428-437, issn 0166-445X, 10 p.Article

Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the ratKAMISAKO, Toshinori; OGAWA, Hiroshi.Journal of gastroenterology and hepatology. 2004, Vol 19, Num 8, pp 879-883, issn 0815-9319, 5 p.Article

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery diseaseTENENBAUM, Alexander; MOTRO, Michael; FISMAN, Enrique Z et al.Circulation (New York, N.Y.). 2004, Vol 109, Num 18, pp 2197-2202, issn 0009-7322, 6 p.Article

Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticalsKOMSTA, Lukasz; MISZTAL, Genowefa; MAJCHRZAK, Ewa et al.Journal of pharmaceutical and biomedical analysis. 2006, Vol 41, Num 2, pp 408-414, issn 0731-7085, 7 p.Article

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinideKAJOSAARI, Lauri I; BACKMAN, Janne T; NEUVONEN, Mikko et al.British journal of clinical pharmacology. 2004, Vol 58, Num 4, pp 390-396, issn 0306-5251, 7 p.Article

Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatographyMASNATTA, L. D; CUNIBERTI, L. A; REY, R. H et al.Journal of chromatography. Biomedical applications. 1996, Vol 687, Num 2, pp 437-442, issn 0378-4347Article

Secondary Prevention With Bezafibrate Therapy for the Treatment of Dyslipidemia : An Extended Follow-Up of the BIP TrialGOLDENBERG, Ilan; BENDERLY, Michal; GOLDBOURT, Uri et al.Journal of the American College of Cardiology. 2008, Vol 51, Num 4, pp 459-465, issn 0735-1097, 7 p.Article

Bezafibrate down-regulates fibrinogen biosynthesis in human hepatoma HepG2 cellsBINSACK, R; STEGMEIER, K; DÖRGE, L et al.European journal of clinical investigation. 1998, Vol 28, Num 2, pp 151-163, issn 0014-2972Article

Bezafibrate administration improves behavioral deficits and tau pathology in P301S miceDUMONT, Magali; STACK, Cliona; CHAN, Robin B et al.Human molecular genetics (Print). 2012, Vol 21, Num 23, pp 5091-5105, issn 0964-6906, 15 p.Article

Physicochemical changes in HDL₃ after bezafibrate treatment : Influence on free cholesterol efflux from human fibroblastsLA VILLE, A. E; SOLA, R; MOTTA, C et al.Cardiovascular drugs and therapy. 1997, Vol 11, Num 5, pp 653-658, issn 0920-3206Article

Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acidTAKEUCHI, Yasuto; IKEDA, Fusao; YAMAMOTO, Kazuhide et al.Journal of gastroenterology and hepatology. 2011, Vol 26, Num 9, pp 1395-1401, issn 0815-9319, 7 p.Article

Protective effect of bezafibrate on streptozotocin-induced oxidative stress and toxicity in ratsANWER, Tarique; SHARMA, Manju; PILLAI, K. K et al.Toxicology (Amsterdam). 2007, Vol 229, Num 1-2, pp 165-172, issn 0300-483X, 8 p.Article

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patientsTENENBAUM, Alexander; MOTRO, Michael; FISMAN, Enrique Z et al.European heart journal. 2005, Vol 26, Num 19, pp 2032-2038, issn 0195-668X, 7 p.Article

A new type of double-layered osmotic pump controlled release tablets of bezafibrate with poor water solubility and large dosageYANG, X; WU, H; NIE, S et al.Journal of drug delivery science and technology. 2008, Vol 18, Num 4, pp 273-277, 5 p.Article

Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia : a nuclear magnetic resonance studyIKEWAKI, Katsunori; NOMA, Kenji; TOHYAMA, Jun-Ichiro et al.International journal of cardiology. 2005, Vol 101, Num 3, pp 441-447, issn 0167-5273, 7 p.Article

Fibrates may Cause an Abnormal Urinary Betaine Loss Which is Associated with Elevations in Plasma HomocysteineLEVER, Michael; GEORGE, Peter M; SLOW, Sandy et al.Cardiovascular drugs and therapy. 2009, Vol 23, Num 5, pp 395-401, issn 0920-3206, 7 p.Article

Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in manGANDINI, R; ASSERETO, R; CASTOLDI, D et al.International journal of clinical pharmacology research. 1987, Vol 7, Num 2, pp 149-155, issn 0251-1649Article

Determination of bezafibrate in human plasma and urine by high-performance liquid chromatographyCASTOLDI, D; MONZANI, V; TOFANETTI, O et al.Journal of chromatography. 1985, Vol 344, pp 259-265, issn 0021-9673Article

STEADY-STATE KINETICS OF BEZAFIBRATE AND CLOFIBRATE IN HEALTHY FEMALE VOLUNTEERSABSHAGEN U; SPORL RADUN S; MARINOW J et al.1980; EUROP. J. CLIN. PHARMACOL.; DEU; DA. 1980; VOL. 17; NO 4; PP. 305-308; BIBL. 15 REF.Article

Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemiaOLSSON, A. G; LANG, P. D; VOLLMAR, J et al.Atherosclerosis. 1985, Vol 55, Num 2, pp 195-1203, issn 0021-9150Article

Der somatostatin-infusionstest zur Beurteilung der Glukose-Utilisation unter Bezafibrat-Medikation = Somatostatine-test pour évaluer l'utilisation du glucose au cours du traitement par bezafibrate = Somatostatin infusion test for the evaluation of glucose utilisation under bezafibrate therapyVOGELBERG, K. H; MÜLLER, H. J; HÜBINGER, A et al.Arzneimittel-Forschung. 1984, Vol 34, Num 9, pp 1038-1041, issn 0004-4172Article

REDUCED LDL- AND INCREASED HDL-APOPROTEINS IN PATIENTS WITH HYPERCHOLESTEROLAEMIA UNDER TREATMENT WITH BEZAFIBRATEMORDASINI R; RIESEN W; OSTER P et al.1981; ATHEROSCLEROSIS; ISSN 0021-9150; NLD; DA. 1981; VOL. 40; NO 2; PP. 153-158; BIBL. 14 REF.Article

Concurrent administration of sustained-release bezafibrate may counteract the increased thrombotic risk associated with oral estrogen therapyMCCARTY, M. F.Medical hypotheses. 2001, Vol 57, Num 2, pp 216-220, issn 0306-9877Article

Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitusRUSTEMEIJER, C; SCHOUTEN, J. A; VOERMAN, H. J et al.Diabetes/metabolism research and reviews (Print). 2000, Vol 16, Num 2, pp 82-87, issn 1520-7552Article